Amryt buys Aegerion via bankruptcy, adding sales to support R&D - Raglan Capital

Home
About Us
Selected Transactions
Raglan IPO Projects
- Raglan Pharmaceutical & Life Science Projects
- Raglan Natural Resources
News
Contact us

Search

Amryt buys Aegerion via bankruptcy, adding sales to support R&D

Home
2019
Amryt buys Aegerion via bankruptcy, adding sales to support R&D

Recent News

Interim Results for 6 months ended 30 June 2020
New £4.3m Challenge Study Contract Win with Global Top 10 Vaccine Company
Open Orphan wins new contract
New £4.3m Challenge Study Contract Win
Open Orphan signs €4.4m contract with global company
Open Orphan wins €4m contract to conduct trial for new RSV treatment

Amryt buys Aegerion via bankruptcy, adding sales to support R&D

25th September 2019

https://otp.investis.com/clients/uk/amryt_pharmaceuticals_dac1/rns/regulatory-story.aspx?cid=1375&newsid=1218097

Prev
Next

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

Join us for our newsletters

Raglan Capital
18 Fitzwilliam Place, Dublin 2.
T: +353 1 6440007
E: info@raglancapital.ie

Contact us
Careers
Privacy Policy
Cookie policy (EU)

© 2020 Raglan Capital. All rights reserved

Privacy Preference Center

Privacy Preferences